Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 08, 2023

SELL
$3.08 - $9.55 $1.69 Million - $5.23 Million
-547,371 Reduced 18.47%
2,415,477 $7.95 Million
Q1 2023

May 12, 2023

BUY
$4.0 - $7.02 $1.08 Million - $1.9 Million
270,000 Added 10.03%
2,962,848 $12.2 Million
Q4 2022

Feb 13, 2023

BUY
$5.65 - $7.86 $1.1 Million - $1.53 Million
195,000 Added 7.81%
2,692,848 $15.8 Million
Q3 2022

Nov 10, 2022

BUY
$4.63 - $8.0 $2.35 Million - $4.06 Million
507,289 Added 25.48%
2,497,848 $16.9 Million
Q2 2022

Aug 03, 2022

BUY
$2.84 - $5.0 $413,890 - $728,680
145,736 Added 7.9%
1,990,559 $9.2 Million
Q1 2022

May 13, 2022

SELL
$3.74 - $6.63 $665,989 - $1.18 Million
-178,072 Reduced 8.8%
1,844,823 $7.36 Million
Q3 2021

Nov 09, 2021

BUY
$8.56 - $14.47 $428,000 - $723,500
50,000 Added 2.53%
2,022,895 $19.1 Million
Q2 2021

Jul 20, 2021

BUY
$13.28 - $18.07 $11.3 Million - $15.4 Million
850,722 Added 75.81%
1,972,895 $26.8 Million
Q1 2021

Apr 29, 2021

BUY
$15.31 - $26.52 $428 - $742
28 Added 0.0%
1,122,173 $28.7 Million
Q4 2020

Jan 22, 2021

BUY
$16.84 - $27.59 $9 Million - $14.7 Million
534,437 Added 90.94%
1,122,145 $29.9 Million
Q3 2020

Oct 19, 2020

SELL
$16.2 - $25.7 $130,167 - $206,499
-8,035 Reduced 1.35%
587,708 $10.9 Million
Q2 2020

Jul 23, 2020

BUY
$5.24 - $23.4 $3.12 Million - $13.9 Million
595,743 New
595,743 $13.9 Million
Q2 2018

Aug 14, 2018

SELL
$14.2 - $22.68 $511,200 - $816,480
-36,000 Closed
0 $0
Q1 2018

May 09, 2018

BUY
$13.56 - $18.48 $325,440 - $443,520
24,000 Added 200.0%
36,000 $568,000
Q4 2017

Feb 07, 2018

BUY
$14.95 - $19.9 $179,400 - $238,799
12,000
12,000 $197,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $59.3M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.